These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8611817)

  • 1. Treatment resistance in schizophrenia.
    Johnstone EC; Sandler R
    BMJ; 1996 Feb; 312(7027):325-6. PubMed ID: 8611817
    [No Abstract]   [Full Text] [Related]  

  • 2. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on polypharmacy in schizophrenia: does anyone truly benefit?
    Goff DC; Freudenreich O
    Int J Neuropsychopharmacol; 2004 Jun; 7(2):109-11. PubMed ID: 15137932
    [No Abstract]   [Full Text] [Related]  

  • 4. D2 antagonist augmentation in patients with a partial response to atypical antipsychotics.
    Mazeh D; Melamed Y; Weizman A
    Can J Psychiatry; 2004 Apr; 49(4):281-2. PubMed ID: 15147030
    [No Abstract]   [Full Text] [Related]  

  • 5. Clozapine treatment of schizophrenia.
    Pickar D; Hsiao JK
    JAMA; 1995 Sep; 274(12):981-3. PubMed ID: 7674530
    [No Abstract]   [Full Text] [Related]  

  • 6. New promises for schizophrenia therapy.
    Sridhar N
    Drug Discov Today; 2002 Feb; 7(4):215-6. PubMed ID: 11839513
    [No Abstract]   [Full Text] [Related]  

  • 7. What is an atypical antipsychotic?
    Reynolds GP
    J Psychopharmacol; 1997; 11(3):195-9. PubMed ID: 9305410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Theory in antipsychotic drug therapy for schizophrenia].
    Tomioka S; Ishigooka J
    Seishin Shinkeigaku Zasshi; 2006; 108(6):614-8. PubMed ID: 16910539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.
    Düring S; Glenthøj BY; Oranje B
    Int J Neuropsychopharmacol; 2015 Oct; 19(3):pyv109. PubMed ID: 26453696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. British Association for Psychopharmacology--2008 Summer Meeting.
    Jenkins TA
    IDrugs; 2008 Oct; 11(10):720-3. PubMed ID: 18828070
    [No Abstract]   [Full Text] [Related]  

  • 11. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational dopamine antagonists for the treatment of schizophrenia.
    Wang SM; Han C; Lee SJ; Jun TY; Patkar AA; Masand PS; Pae CU
    Expert Opin Investig Drugs; 2017 Jun; 26(6):687-698. PubMed ID: 28443355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis: a reply.
    Lako IM; Liemburg EJ; Van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2014 Aug; 34(4):532-3. PubMed ID: 24949704
    [No Abstract]   [Full Text] [Related]  

  • 15. Challenging the need for sustained blockade of dopamine D₂ receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study.
    Tsuboi T; Suzuki T; Bies RR; Remington G; Pollock BG; Mimura M; Uchida H
    Schizophr Res; 2015 May; 164(1-3):149-54. PubMed ID: 25864950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls.
    Lee J; Takeuchi H; Remington G
    J Clin Psychopharmacol; 2014 Aug; 34(4):530-2. PubMed ID: 24875070
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
    Nakata Y; Kanahara N; Iyo M
    J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics.
    Mizrahi R; Mamo D; Rusjan P; Graff A; Houle S; Kapur S
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):715-21. PubMed ID: 19366489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
    Lieberman JA; Bymaster FP; Meltzer HY; Deutch AY; Duncan GE; Marx CE; Aprille JR; Dwyer DS; Li XM; Mahadik SP; Duman RS; Porter JH; Modica-Napolitano JS; Newton SS; Csernansky JG
    Pharmacol Rev; 2008 Sep; 60(3):358-403. PubMed ID: 18922967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.
    Moriguchi S; Bies RR; Remington G; Suzuki T; Mamo DC; Watanabe K; Mimura M; Pollock BG; Uchida H
    J Clin Psychopharmacol; 2013 Oct; 33(5):682-5. PubMed ID: 23899638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.